. Additionally, in cancer patients there is ample evidence for immunological control of tumors. First, tumor-specific immunity can be detected in a proportion of cancer patients [6] . Second, the risk of developing a tumor greatly increases in immunocompromised patients, such as AIDS patients or organ transplant recipients. Third, correlative studies indicate that the presence of tumor-infiltrating lymphocytes may be associated with improved clinical outcome in several cancers including melanoma, colorectal, breast, prostate, renal cell, esophageal and ovarian carcinomas [7] [8] [9] [10] [11] [12] [13] . In particular, recent data in epithelial ovarian cancer indicated significant differences in the distributions of progression-free survival and overall survival according to the presence or absence of intratumoral T cells. The five-year overall survival rate was 38.0% among patients whose tumors contained T cells and 4.5% among patients whose tumors did not. In addition, ovarian cancer patients, whose tumors are infiltrated by CD4+CD25+FoxP3+ regulatory T cells (T reg ), demonstrated reduced survival [14] . Fourth, after transplanting kidneys from a patient who died of a stroke and was supposedly cured of an early stage melanoma 16 years back to two independent recipients, both recipients developed donor-derived metastatic melanoma under immunosuppressive treatment [15] .
Tumors escape destruction by the immune system via a variety of active, regulatory mechanisms. These include downregulation of major histocompatibility complex (MHC) molecules and/or the immunologically targeted antigens by the tumor cells, stimulation of inhibitory receptors such as cytotoxic T lymphocyte antigen-4 (CTLA-4) or PD-1 on T cells, induction of increased tumor infiltration by regulatory CD4+CD25+FoxP3+ T cells (T reg ), or the production of immunosuppressive mediators such as IL-10, TGF-␤ , indoleamine 2,3-dioxygenase by the tumor cells, stroma or infiltrate [2] . The often patchy expression of MHC molecules and tumor-associated antigens in tumor biopsies is indicative of the dynamic process of tumor escape, and it was observed in some clinical vaccination studies that the new metastases, which developed after initial clinical response, lost expression of MHC class I or of the targeted antigen.
CTLA-4 is one of the crucial negative regulators of the adaptive immune response and it is known now that CTLA-4 has a central role in the induction and maintenance of peripheral T cell tolerance. This is illustrated by the fact that mice lacking CTLA-4 die of generalized autoimmunity and inflammation at the age of 3 weeks [16] . It is thought that peripheral T cell tolerance occurs in cancer patients as a result of chronic and suboptimal antigen stimulation and of the self-nature of many tumorassociated antigens and that this limits T cell-mediated anti-tumor effector responses. For this reason, the therapeutic effect of CTLA-4 blocking antibodies was tested in mouse models and cancer patients, and showed encouraging results. Currently, clinical studies are being performed in which anti-CTLA-4 treatment is combined with simultaneous immunization, which is expected to have a higher efficacy than CTLA-4 blockade alone. PD-1 is another molecule that is expressed on T cells and is involved in induction and maintenance of peripheral T cell tolerance. There is evidence that the ligands for PD-1, PD-L1 and PD-L2 are expressed by a proportion of tumor cells, and the first clinical studies in which cancer patients receive treatment with monoclonal antibodies that block PD-1 are being performed at present.
CD4+CD25+FoxP3+ T reg are crucial in preventing immune responses to self-antigens. They do this by interfering with the maturation of dendritic cells and by directly suppressing effector T cells (T eff ) through cell-cell interactions and/or soluble factors, including CTLA-4, IL-10 and TGF-␤ . The percentage of T reg in the peripheral blood of healthy individuals and cancer patients is similar and is 2-5% of CD4+ cells. In tumors, however, this percentage is often dramatically increased, such that the ratio of T eff to T reg is low. Retrospective analysis in patients with ovarian carcinoma showed a correlation between the T eff to T reg ratio and survival time, with a low ratio being a poor prognostic factor [17] . Patients with prostate cancer who were treated with anti-CTLA-4 and had a clinical response showed an increase in the T eff to T reg ratio in some cases. In addition, T reg depletion in different mouse models for cancer resulted in better tumorspecific T cell responses and a better control of tumors [18] .
Antigen Discovery and Classes of Tumor-Associated Antigens
The era of modern cancer immunology started with observations made in two patients (SK-29 and MZ-2) with recurrent metastatic melanoma, who have been observed since 1978 and 1982, respectively. Both patients received intradermal immunizations with irradiated autologous tumor cells for an extended period of time and complete regression of tumor manifestations in the presence of T cell responses and strong increasing T cell responses under vaccination was documented. The patients, still alive, have remained free of disease ever since (for more than 2 decades now). Based on this favorable clinical effect, a systematic search was initiated to identify and characterize the cancer antigens and immune effector mechanisms that mediate tumor regression and tumor control in vivo. A few years later, the first reports on spontaneous tumor-specific T cell responses were published [19] . Thierry Boon and colleagues cloned the first T cell-defined human cancer antigens from these patients in 1991: MAGE-1, tyrosinase and Melan-A. Since the initial reports by Boon and colleagues [20] , a large number of tumor-associated antigens have been identified using similar approaches, e.g. BAGE, GAGE, and many others.
Some antigens were identified by serological analysis of recombinant cDNA expression libraries (SEREX):
here, an expression library is incubated with patient serum, the cDNA clones that are recognized by the serum IgG are isolated, and the recognized protein is cloned and identified [21] . Examples of tumor-associated antigens that were identified by SEREX are SSX, NY-ESO-1, CT7, Rab38, NY-CO-58 and NY-BR-1.
Besides SEREX-and T cell-defined antigens, some antigens were discovered by cancer-induced antibodies. Typically, these antigens are (over)expressed on the surface of cancer cells and include gp75/TRP-1, p96 and Her2/neu.
Nowadays, tumor-associated antigens are classified into one of the following categories: (1) cancer-testis (CT) antigens, restricted expression in germ cells and cancer cells, e.g. MAGE, NY-ESO-1 and LAGE-1; (2) differentiation antigens, restricted to defined lineages like melanocytes, e.g. tyrosinase, Melan-A/MART-1 and gp 100; (3) mutated antigens, altered forms of constitutive proteins, e.g. CDK4, ␤ -catenin, caspase-8 and p53; (4) amplification antigens, e.g. overexpressed Her2/neu and p53; (5) splice variant antigens, e.g. NY-CO-37/PDZ-45 and ING1; (6) glycolipid antigens; (7) viral antigens, e.g. HPV, EBV.
Among all tumor antigens identified to date, the CT antigens are a distinct and unique class of differentiation antigens. The genes encoding CT antigens are frequently located on the X chromosome and are often members of multi-gene families. Furthermore, 10% of all genes on the X chromosome are CT antigens [22] . CT antigens are not expressed in healthy tissues, except germ cells, but are expressed by a proportion of different tumor types in a lineage-nonspecific fashion. Often, a particular tumor expresses more than one CT antigen. The frequency of CT antigen expression in many cancer types ranges from 5-40%, with exceptionally high expression of individual CT antigens in certain cancers, e.g. high expression of MAGE-C1/CT7 in myeloma and NY-ESO-1 in 80% of synovial sarcoma [23, 24] . The function of CT antigens in germ cells and malignant cells is largely unknown. How their expression is regulated is also not known at present, but recent evidence suggests that epigenetic events, including DNA methylation and histone deacetylation, play a role. Some well-characterized members of the CT antigen family include MAGE, GAGE/PAGE/XAGE, NY-ESO-1/LAGE-1, SSX, SPANX, TRAG-3, BAGE, SCP-1, OY-TES-1 and CT10 [22, 25] .
Integrated Immune Responses in Cancer Patients: The NY-ESO-1 Paradigm

NY-ESO-1 was initially identified by SEREX in New
York from a patient with esophageal cancer, hence its name. NY-ESO-1 is a protein of 180 amino acids with a molecular weight of approximately 18 kDa, and its coding gene is located on the X chromosome (Xq28) [21] . The expression of NY-ESO-1 in healthy tissue is restricted to testicular germ cells, fetal ovary germ cells and trophoblastic epithelia of placental villi, all of which are MHC class I-negative. NY-ESO-1 is expressed at a variable frequency in several tumor types ( fig. 1 ) and is considered to be the most immunogenic CT antigen to date. It elicits both cellular and humoral immune responses in a high proportion of patients with NY-ESO-1-expressing tumors [26] . These spontaneously occurring immune responses in cancer patients strongly support the concept of immunosurveillance. Several MHC class I-and class II-restricted epitopes from NY-ESO-1, which are recognized by CD8+ cytotoxic and CD4+ helper T cells, respectively [27, 28] , have been characterized. These include epitopes restricted by MHC molecules that are relatively common in the Caucasian population such as the MHC class I molecules HLA-A2, HLA-A24 and HLA-B35, as well as the MHC class II molecules HLA-DR4 and HLA-DP4. These achievements are particularly important because they facilitate the monitoring of vaccine-induced and spontaneous immune responses in cancer patients. Because the primary tumor was never detected, the interpretation is that it was controlled and eventually eliminated by the spontaneous NY-ESO-1-specific immunity, an example of effective immune surveillance in vivo. The patient responded to rFV/ NY-ESO-1 immunization with increased humoral and cellular immunity against NY-ESO-1, which was presumably responsible for the initial control and remission of disease. We assume that the subsequent NY-ESO-1 -metastases developed as a result of immunological pressure and can be seen as an example of immunoediting.
Immunotherapy as an Integrated Approach in Cancer Treatment
After two decades of immunotherapy in preclinical models for cancer and patients, it is clear that significant hurdles, which prevent the induction of sustained tumorspecific effector functions in cancer patients, exist. The major aim for cancer immunotherapy is to identify these hurdles and to design treatments to circumvent these. The field of immunoregulation has made great progress during the last years, and many of the cells and factors involved in immunoregulation seem to impinge on tumor-specific immunity as well. First, tumor-specific T cells may be unable to infiltrate the tumor. Second, tumor antigens may be (ectopically) expressed in the thymus, which may purge the repertoire of tumor-specific T cells from high-avidity clones. Third, tumor-derived antigens are presumably presented to naïve T cells by steady-state dendritic cells, which may result in robust peripheral T cell tolerance. Fourth, chronic presentation of antigen may functionally or physically exhaust specific effector cells. Fifth, regulatory T cells in the tumor microenvironment block local T cell function or block the priming of tumor-specific T cells. Finally, the tumor environment may produce soluble factors, such as IL-10 and TGF-␤ , or promote the presence of myeloid-derived suppressor cells, all of which locally suppress T cell effector function.
The ultimate goal of cancer immunotherapy is to immunize patients with a tumor-associated antigen together with an adjuvant to stimulate innate immune defense. Because the immune system evolved to combat pathogens, immunization under conditions that mimic an infection is considered to be crucial for the induction of protective immunity. Compared to prophylactic vaccination, where an immune response is induced with a foreign antigen, therapeutic vaccination has proven to be more demanding. It is thought that prolonged antigen presentation under noninflammatory conditions, which may occur during persistent viral infections such as HBV or HIV or in cancer patients, results in subversion of the immune response by (partial) tolerization or exhaustion of specific T cells. Thus, besides an immunogenic antigen and an adjuvant, the vaccine presumably must contain a treatment modality that interferes with ongoing immunoregulation in order to be effective in cancer patients.
At present, clinical trials are under way that integrate the issues discussed above. For instance, treatment with antibodies that block CTLA-4 or PD-1 have resulted in objective clinical responses in some patients. It may be worth designing trials that combine both antibodies, as there is evidence that both regulatory pathways are nonredundant. It is only recently that trials have started in which blockade of CTLA-4 or PD-1 is combined with active immunization or with active immunization plus preceding lymphodepletion. The latter approach may be promising, as lymphodepletion removes many regulatory In addition to vaccination with recombinant pathogens, recombinant proteins or (long) peptides in order to induce an integrated (antibodies and T cells) and tumorspecific immune response, the therapeutic potential of antibodies against tumor-associated, intracellular antigens is being investigated. To this end, we generated a fully human monoclonal IgG that recognizes NY-ESO-1. We cloned the B cell receptor (IgG) from EBV-transformed B cells of a cancer patient with high titers of spontaneous IgG against NY-ESO-1 and produced the human monoclonal IgG as a recombinant protein. The advantage of this approach is that we generate antibodies that are biologically relevant and probably safe, as they were derived directly from patients. We propose that high levels of NY-ESO-1-specific IgG will localize to otherwise damaged tumor tissues and form immune complexes with NY-ESO-1 that is released from apoptotic or necrotic tumors. Those immune complexes will subsequently be taken up efficiently by dendritic cells for antigen presentation to NY-ESO-1-specific T cells. Cell death or necrosis of tumors, and thus presumably the therapeutic effect of antibodies, can be enhanced by radiotherapy, chemotherapy or other tumoricidal interventions. At present, patient-derived cancer-specific antibodies are highly promising agents for the initiation of an integrated tumor-specific immune response in cancer patients in the context of multimodal treatment approaches to combat cancer.
